2000年至2018年美国肠病相关T细胞淋巴瘤患者:SEER数据库分析

Q3 Medicine
Ahmed K. Awad , Rehmat Ullah Awan , Ayman K. Awad , Ambreen Nabeel , Sophia Dar , Ayokunle T. Abegunde
{"title":"2000年至2018年美国肠病相关T细胞淋巴瘤患者:SEER数据库分析","authors":"Ahmed K. Awad ,&nbsp;Rehmat Ullah Awan ,&nbsp;Ayman K. Awad ,&nbsp;Ambreen Nabeel ,&nbsp;Sophia Dar ,&nbsp;Ayokunle T. Abegunde","doi":"10.1016/j.ctarc.2023.100745","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Enteropathy-Associated T-Cell Lymphoma (EATL) is a rare lymphoma of T-cell origin associated with celiac disease. There is limited evidence in the literature about the incidence and causes of death in patients with EATL.</p></div><div><h3>Methods</h3><p>We performed a retrospective study through analyzing the Surveillance, Epidemiology, and End Results (SEER) data base to determine the incidence, trends and causes of death of patients with EATL in the U.S from 2000 to 2018. Baseline characteristics with treatment options (surgery, radiotherapy, and chemotherapy), status of patients either alive, dead due to cancer itself or other non-cancerous causes with listing of those non-cancerous causes was retrieved. Sub-group analysis based on sex was also done. Multiple latency periods (&lt;2 year, 2–5, 6–10, 11–15, and more than 15 years) were analyzed following EATL diagnosis.</p></div><div><h3>Results</h3><p>There were 259 EATL patients, majority were aged 70–74 years old (<em>n</em> = 36, 13.9%), predominantly males 155 (59.8%), most common in whites, (76.4%, <em>n</em> = 198), EATL was the only primary tumor in 177 (68.3%) cases, most common site was small bowel at different sites 84 (32.4%) followed by jejunum specifically 57 (22%), majority went for surgical resection (69.9%, <em>n</em> = 181) followed by chemotherapy (47.5%, <em>n</em> = 123), 217 (83.7%) died during follow-up in this study,</p></div><div><h3>Conclusion</h3><p>EATL is a rare entity, mostly seen in males, between 70 and 74 years, and mostly originated in the small bowel. With over 80% death in five-year follow up period, EATL patients showed better survival if they underwent chemotherapy. More studies are needed for further understanding of this rare entity.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Patients with enteropathy-associated T-cell lymphoma in the United States from 2000 to 2018: SEER data-base analysis\",\"authors\":\"Ahmed K. Awad ,&nbsp;Rehmat Ullah Awan ,&nbsp;Ayman K. Awad ,&nbsp;Ambreen Nabeel ,&nbsp;Sophia Dar ,&nbsp;Ayokunle T. Abegunde\",\"doi\":\"10.1016/j.ctarc.2023.100745\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Enteropathy-Associated T-Cell Lymphoma (EATL) is a rare lymphoma of T-cell origin associated with celiac disease. There is limited evidence in the literature about the incidence and causes of death in patients with EATL.</p></div><div><h3>Methods</h3><p>We performed a retrospective study through analyzing the Surveillance, Epidemiology, and End Results (SEER) data base to determine the incidence, trends and causes of death of patients with EATL in the U.S from 2000 to 2018. Baseline characteristics with treatment options (surgery, radiotherapy, and chemotherapy), status of patients either alive, dead due to cancer itself or other non-cancerous causes with listing of those non-cancerous causes was retrieved. Sub-group analysis based on sex was also done. Multiple latency periods (&lt;2 year, 2–5, 6–10, 11–15, and more than 15 years) were analyzed following EATL diagnosis.</p></div><div><h3>Results</h3><p>There were 259 EATL patients, majority were aged 70–74 years old (<em>n</em> = 36, 13.9%), predominantly males 155 (59.8%), most common in whites, (76.4%, <em>n</em> = 198), EATL was the only primary tumor in 177 (68.3%) cases, most common site was small bowel at different sites 84 (32.4%) followed by jejunum specifically 57 (22%), majority went for surgical resection (69.9%, <em>n</em> = 181) followed by chemotherapy (47.5%, <em>n</em> = 123), 217 (83.7%) died during follow-up in this study,</p></div><div><h3>Conclusion</h3><p>EATL is a rare entity, mostly seen in males, between 70 and 74 years, and mostly originated in the small bowel. With over 80% death in five-year follow up period, EATL patients showed better survival if they underwent chemotherapy. More studies are needed for further understanding of this rare entity.</p></div>\",\"PeriodicalId\":9507,\"journal\":{\"name\":\"Cancer treatment and research communications\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment and research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468294223000679\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294223000679","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景肠病相关T细胞淋巴瘤(EATL)是一种罕见的与乳糜泻相关的T细胞淋巴瘤。文献中关于EATL患者的发病率和死因的证据有限。方法我们通过分析监测、流行病学和最终结果(SEER)数据库进行了一项回顾性研究,以确定2000年至2018年美国EATL患者发病率、趋势和死因。检索治疗方案(手术、放疗和化疗)的基线特征、癌症本身或其他非癌症原因导致的患者的存活或死亡状态,并列出这些非癌症原因。还进行了基于性别的分组分析。EATL诊断后分析了多个潜伏期(<;2年、2-5年、6-10年、11-15年和超过15年)。结果共有259例EATL患者,大多数年龄在70–74岁(n=36,13.9%),主要是男性155例(59.8%),最常见于白人(76.4%,n=198),177例(68.3%)EATL是唯一的原发性肿瘤,最常见的部位是不同部位的小肠84例(32.4%),其次是空肠57例(22%),大多数患者进行了手术切除(69.9%,n=181),然后进行了化疗(47.5%,n=123),217人(83.7%)在本研究的随访中死亡。结论EATL是一种罕见的疾病,多见于70至74岁的男性,主要起源于小肠。在五年的随访期内,超过80%的患者死亡,如果接受化疗,EATL患者的生存率会更好。需要更多的研究来进一步了解这种罕见的实体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Patients with enteropathy-associated T-cell lymphoma in the United States from 2000 to 2018: SEER data-base analysis

Background

Enteropathy-Associated T-Cell Lymphoma (EATL) is a rare lymphoma of T-cell origin associated with celiac disease. There is limited evidence in the literature about the incidence and causes of death in patients with EATL.

Methods

We performed a retrospective study through analyzing the Surveillance, Epidemiology, and End Results (SEER) data base to determine the incidence, trends and causes of death of patients with EATL in the U.S from 2000 to 2018. Baseline characteristics with treatment options (surgery, radiotherapy, and chemotherapy), status of patients either alive, dead due to cancer itself or other non-cancerous causes with listing of those non-cancerous causes was retrieved. Sub-group analysis based on sex was also done. Multiple latency periods (<2 year, 2–5, 6–10, 11–15, and more than 15 years) were analyzed following EATL diagnosis.

Results

There were 259 EATL patients, majority were aged 70–74 years old (n = 36, 13.9%), predominantly males 155 (59.8%), most common in whites, (76.4%, n = 198), EATL was the only primary tumor in 177 (68.3%) cases, most common site was small bowel at different sites 84 (32.4%) followed by jejunum specifically 57 (22%), majority went for surgical resection (69.9%, n = 181) followed by chemotherapy (47.5%, n = 123), 217 (83.7%) died during follow-up in this study,

Conclusion

EATL is a rare entity, mostly seen in males, between 70 and 74 years, and mostly originated in the small bowel. With over 80% death in five-year follow up period, EATL patients showed better survival if they underwent chemotherapy. More studies are needed for further understanding of this rare entity.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
148
审稿时长
56 days
期刊介绍: Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信